Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
NCT07718126 on ClinicalTrials.gov · last registry update 2026-09-23
Recruiting now, toward 60 participants. Due to report 28 February 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Proportion of Participants Achieving Resolution of MASLD Without Worsening of Liver Fibrosis (ROM). Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 3 times since then.
- Status
- RECRUITING
- Phase
- P4
- Drug
- mazdutide
- Sponsor
- West China Hospital
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2026-09-01
- Primary completion
- 2029-02-28 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-23 | Reporting date moved | 2028-08-31 → 2029-02-28 6 months later |
| 2026-09-23 | Status changed | NOT_YET_RECRUITING → RECRUITING |
| 2026-09-23 | Record changed | P2/P3 → P4 |
Primary outcome
Proportion of Participants Achieving Resolution of MASLD Without Worsening of Liver Fibrosis (ROM)
Conditions studied
Metabolic Dysfunction-Associated Steatohepatitis · Hepatic Steatosis · Living Liver Donors
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.